The Cost of Interventions to Increase Influenza Vaccination: A Systematic Review.

Laura J Anderson, Paul Shekelle, Emmett Keeler, Lori Uscher-Pines, Roberta Shanman, Sally Morton, Gursel Aliyev, Teryl K Nuckols
Author Information
  1. Laura J Anderson: Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California; Department of Epidemiology, UCLA Jonathan and Karin Fielding School of Public Health, University of California-Los Angeles, Los Angeles, California. Electronic address: laura.anderson@cshs.org.
  2. Paul Shekelle: Evidence-based Synthesis Program, West Los Angeles VA Medical Center, Los Angeles, California; Rand Health, RAND Corporation, Santa Monica, California.
  3. Emmett Keeler: Rand Health, RAND Corporation, Santa Monica, California.
  4. Lori Uscher-Pines: Rand Health, RAND Corporation, Santa Monica, California.
  5. Roberta Shanman: Rand Health, RAND Corporation, Santa Monica, California.
  6. Sally Morton: Department of Statistics, Virginia Polytechnic Institute and State University, Blacksburg, Virginia.
  7. Gursel Aliyev: Rand Health, RAND Corporation, Santa Monica, California.
  8. Teryl K Nuckols: Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California; Rand Health, RAND Corporation, Santa Monica, California.

Abstract

CONTEXT: influenza vaccination rates remain below Healthy People 2020 goals. This project sought to systematically review economic evaluations of healthcare-based quality improvement interventions for improving influenza vaccination uptake among general populations and healthcare workers.
EVIDENCE ACQUISITION: The databases MEDLINE, Econlit, Centre for Reviews & Dissemination, Greylit, and Worldcat were searched in July 2016 for papers published from January 2004 to July 2016. Eligible studies evaluated efforts by bodies within the healthcare system to encourage influenza vaccination by means of an organizational or structural change. For each study, program costs per enrollee and per additional enrollee vaccinated were derived (excluding vaccine costs, standardized to 2017 U.S. dollars). Complete economic evaluations were examined when available.
EVIDENCE SYNTHESIS: Of 2,350 records, 18 articles were eligible and described 29 unique interventions. Most interventions improved vaccine uptake. Among 23 interventions in general populations, the median program cost was $3.27 (interquartile range, $0.82-$11.53) per enrollee and $50.78 (interquartile range, $27.85-$124.84) per additional enrollee vaccinated. Among ten complete economic evaluations in general populations, three studies reported net cost savings, four reported costs <$50,000 per quality-adjusted life year, and three reported costs <$60,000 per life saved. Among six interventions in healthcare workers, the median program cost was $8.09 (interquartile range, $5.03-$10.31) per worker enrolled and $125.24 (interquartile range, $96.06-$171.38) per additional worker vaccinated (there were no complete economic analyses).
CONCLUSIONS: Quality improvement interventions for influenza vaccination involve per-enrollee costs that are similar to the cost of the vaccine itself ($11.78-$36.08/dose). Based on limited available evidence in general populations, quality improvement interventions may be cost saving to cost effective for the health system.

References

  1. N Engl J Med. 2014 Aug 28;371(9):796-7 [PMID: 25162885]
  2. Ann Intern Med. 2009 Aug 18;151(4):264-9, W64 [PMID: 19622511]
  3. Vaccine. 2013 Nov 4;31(46):5339-48 [PMID: 24055351]
  4. Vaccine. 2017 Apr 4;35(15):1828-1843 [PMID: 28284681]
  5. PLoS Med. 2015 Oct 19;12(10):e1001889 [PMID: 26479077]
  6. JAMA Intern Med. 2016 Dec 1;176(12):1843-1854 [PMID: 27775764]
  7. Can J Public Health. 2014 Jul 11;105(4):e312-6 [PMID: 25166135]
  8. Health Aff (Millwood). 2016 Feb;35(2):284-92 [PMID: 26858382]
  9. Infect Control Hosp Epidemiol. 2010 Sep;31(9):881-8 [PMID: 20653445]
  10. J Am Pharm Assoc (2003). 2008 Nov-Dec;48(6):758-63 [PMID: 19019805]
  11. Infect Control Hosp Epidemiol. 2011 Apr;32(4):375-9 [PMID: 21460489]
  12. MMWR Morb Mortal Wkly Rep. 2014 Sep 19;63(37):805-11 [PMID: 25233281]
  13. Br J Gen Pract. 2002 Sep;52(482):712-6 [PMID: 12236273]
  14. MMWR Recomm Rep. 2016 Aug 26;65(5):1-54 [PMID: 27560619]
  15. Vaccine. 2012 Jun 13;30(28):4175-81 [PMID: 22546332]
  16. Am J Infect Control. 2015 Jun;43(6):624-8 [PMID: 25798775]
  17. Vaccine. 2007 Jun 28;25(27):5086-96 [PMID: 17544181]
  18. Med Care. 2003 Jan;41(1):32-44 [PMID: 12544542]
  19. J Hosp Med. 2008 Mar;3(2):134-41 [PMID: 18438789]
  20. Vaccine. 2006 Nov 17;24(47-48):7003-8 [PMID: 16730866]
  21. Public Health Rep. 2013 Jan-Feb;128(1):7-25 [PMID: 23277655]
  22. Cochrane Database Syst Rev. 2014 Jul 07;(7):CD005188 [PMID: 24999919]
  23. Vaccine. 2010 Jul 12;28(31):4913-9 [PMID: 20576536]
  24. BMC Public Health. 2014 Jul 15;14:718 [PMID: 25023889]
  25. Am J Manag Care. 2008 Nov;14(11):748-54 [PMID: 18999909]
  26. Cochrane Database Syst Rev. 2010 Sep 08;(9):CD005188 [PMID: 20824843]
  27. J Occup Environ Med. 2015 Jan;57(1):58-61 [PMID: 25563540]
  28. Vaccine. 2007 Aug 29;25(35):6511-21 [PMID: 17681651]
  29. Vaccine. 2005 Mar 18;23(17-18):2256-60 [PMID: 15755606]
  30. Pediatrics. 2006 Nov;118(5):e1321-7 [PMID: 17079533]
  31. Qual Saf Health Care. 2010 Aug;19(4):279-83 [PMID: 20630931]
  32. Hum Vaccin Immunother. 2013 Jul;9(7):1500-11 [PMID: 23732900]
  33. Am J Prev Med. 2001 Nov;21(4):256-60 [PMID: 11701294]
  34. BMJ Open. 2016 Feb 19;6(2):e010069 [PMID: 26895984]
  35. Vaccine. 2006 Jun 5;24(23):4934-41 [PMID: 16678945]
  36. Am J Prev Med. 2014 Sep;47(3):330-40 [PMID: 25145618]
  37. Vaccine. 2011 Nov 21;29(50):9398-403 [PMID: 21945495]
  38. Hum Vaccin Immunother. 2012 Jan;8(1):119-29 [PMID: 22251999]
  39. Jt Comm J Qual Patient Saf. 2012 Feb;38(2):67-72 [PMID: 22372253]
  40. Vaccine. 2009 Nov 23;27(50):7110-5 [PMID: 19786135]
  41. Am J Manag Care. 2015 Jul 01;21(7):e405-13 [PMID: 26295268]
  42. Ann Fam Med. 2012 Nov-Dec;10(6):538-46 [PMID: 23149531]
  43. Am J Emerg Med. 2012 Sep;30(7):1072-9 [PMID: 21908140]
  44. Pharmacoeconomics. 2008;26(2):163-78 [PMID: 18198935]
  45. Am J Prev Med. 2005 Jun;28(5 Suppl):231-7 [PMID: 15894158]
  46. BMJ Qual Saf. 2015 Dec;24(12):796-804 [PMID: 26311020]
  47. Am J Prev Med. 2005 Oct;29(3):221-6 [PMID: 16168873]
  48. Clinicoecon Outcomes Res. 2011;3:89-104 [PMID: 21935337]
  49. Int J Technol Assess Health Care. 2009 Oct;25(4):522-9 [PMID: 19845982]
  50. BMJ Open. 2016 Feb 16;6(2):e009739 [PMID: 26883237]
  51. Vaccine. 2007 Feb 9;25(8):1484-96 [PMID: 17156901]

Grants

  1. R01 HS022644/AHRQ HHS

MeSH Term

Cost Savings
Cost of Illness
Cost-Benefit Analysis
Humans
Immunization Programs
Influenza Vaccines
Influenza, Human
Mass Vaccination
Quality Improvement
Quality-Adjusted Life Years

Chemicals

Influenza Vaccines

Word Cloud

Created with Highcharts 10.0.0perinterventionscostcostsvaccinationeconomicgeneralpopulationsenrolleeinterquartilerangeevaluationsimprovementinfluenzahealthcareprogramadditionalvaccinatedvaccineAmongreportedInfluenzaqualityuptakeworkersEVIDENCEJuly2016studiessystemavailablemediancompletethree000lifeworkerCONTEXT:ratesremainHealthyPeople2020goalsprojectsoughtsystematicallyreviewhealthcare-basedimprovingamongACQUISITION:databasesMEDLINEEconlitCentreReviews&DisseminationGreylitWorldcatsearchedpaperspublishedJanuary2004Eligibleevaluatedeffortsbodieswithinencouragemeansorganizationalstructuralchangestudyderivedexcludingstandardized2017USdollarsCompleteexaminedSYNTHESIS:2350records18articleseligibledescribed29uniqueimproved23$327$082-$1153$5078$2785-$12484tennetsavingsfour<$50quality-adjustedyear<$60savedsix$809$503-$1031enrolled$12524$9606-$17138analysesCONCLUSIONS:Qualityinvolveper-enrolleesimilar$1178-$3608/doseBasedlimitedevidencemaysavingeffectivehealthCostInterventionsIncreaseVaccination:SystematicReview

Similar Articles

Cited By (9)